Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 130-139 , September 2010

Management of Trastuzumab-Related Cardiac Dysfunction

  • Joseph R. Carver

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Joseph R. Carver, MD, FACC, Chief of Staff, Clinical Professor, Abramson Cancer Center of The University of Pennsylvania, 1600 Penn Tower, Philadelphia, PA 19104.

References 

  1. Park JW, Neve RM, Szollosi J, et al. Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer. 2008;8:392–401
  2. Sjogren S, Inganas M, Lindgren A, et al. Progressive and predictive value of c-erB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16:462–469
  3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancerL correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  4. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5:63–69
  5. Press MF, Pike MC, Chazin G, et al. Her-2/neu expression in node-negative breast cancer: Direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53:4960–4970
  6. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894–2904
  7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  9. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. (abstr 512) J Clin Oncol. 2007;25:6s
  10. Slamon DJ, Eiermann W, Robert NJ, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER-2 positive early breast cancer patients: BCIRG 006 study. (abstr 1) Breast Cancer Res Treat. 2005;94(Suppl 1):S5
  11. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: phase III Trial comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis. (abstr 62) In: Presented at SABCS. 2009;
  12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  13. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–1221
  14. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24:4107–4115
  15. Seidman AD, Fornier MN, Esteva FJ. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19:2587–2595
  16. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B Protocol 9840. J Clin Oncol. 2008;26:1642–1649
  17. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2006;24:2786–2792
  18. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol. 2005;23:4265–4274
  19. Pegram M, Forbes JF, Pienkowski T, et al. First overall survival analysis of a multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as, first line chemotherapy for patients with metastatic breast cancer containing the HER2/neu alteration. (abstr LBA1008) J Clin Oncol. 2007;25:34s
  20. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003;21:2889–2895
  21. O’Shaughnessy J, Vukelja SJ, Marsland T, et al. Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin Breast Cancer. 2002;3(Suppl 1):17–20
  22. Wardley A, Antón-Torres A, Pivot X, et al. Evaluation of trastuzumab (Herceptin), docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. (abstr 309) Breast Cancer Res Treat. 2007;106(Suppl 1):S33
  23. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811–7819
  24. Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction on NSABP B-31. A randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab. (abstr LBA513) J Clin Oncol. 2007;25:6s
  25. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231–1238
  26. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events in the Herceptin adjuvant trial. J Clin Oncol. 2007;25:3859–3865
  27. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27:5685–5692
  28. Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378:394–398
  29. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459–465
  30. Negro A, Brar BK, Lee K. Essential roles of HER2/erbB2 in cardiac development and function. Recent Prog Horm Res. 2004;59:1–12
  31. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332–344
  32. Chien KR. Herceptin and the heart. A molecular modifier of cardiac failure. N Engl J Med. 2006;354:789–790
  33. Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem. 1998;273:10261–10269
  34. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest. 1980;65:128–135
  35. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900–2902
  36. Ewer MS, O'Shaughnessy JA. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer. 2007;7:600–607
  37. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820–7826
  38. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004;22:322–329
  39. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for diagnosis and treatment of heart failure in adults. J Am Col Card. 2009;53:1343–1382
  40. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991–4008
  41. Fox KF. The evaluation of left ventricular function for patients being considered for or receiving Trastuzumab (Herceptin) therapy. Brit J Cancer. 2006;95:1454
  42. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers. Drug Saf. 2002;25:301–3011
  43. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749–2754
  44. Lenihan D, Massey MR, Baysinger KB, et al. Superior detection of cardiotoxicity during chemotherapy using biomarkers. (abstr 265) J Card Fail. 2007;13(6 Suppl 2):S151
  45. Kutteh LA, Hobday T, Jaffe A, et al. A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer. (2007 ASCO annual meeting proceedings) J Clin Oncol. 2007;25(Suppl 18S):579
  46. National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Breast cancer. V.1.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdfAccessed March 31, 2009
  47. Shenoy M, Chapman CB, Nawaz MZ, et al. Diagnosis and management of stage A heart failure. Congest Heart Fail. 2006;12146–12152
  48. Ewer MS, Perez EA, Baselga J, et al. Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin) in HER2-positive early breast cancer. Breast. 2007;16(Suppl 1):S63
  49. Heart Failure Society of America. Management of asymptomatic patients with reduced left ventricular ejection fraction. J Card Fail. 2006;12:e26–e28
  50. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95:1592–1600
  51. Lenihan D, Tong A, Divakaran V, et al. Herceptin (T)–associated cardiomyopathy: sequential stress and response to ACE-inhibitors and carvedilol therapy. (abst 383) J Card Fail. 2003;9(5 Suppl 1):S102
  52. Lenihan D, Tong A, Woods M, et al. Withdrawal of beta blockers and ACE inhibitors in chemotherapy-induced heart failure leads to severe adverse cardiovascular events. (abstr 281) J Card Fail. 2003;9(5 Suppl 1):S77
  53. van der Harst P, Voors AA, van Gilst WH, et al. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res. 2006;71:443–454
  54. Haendeler J, Hoffmann J, Zeiher AM, et al. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation. 2004;110:856–861
  55. Pocobelli G, Newcomb PA, Trentham-Dietz A, et al. Statin use and risk of breast cancer. Cancer. 2008;112:27–33

 Statement of Conflict of Interest: see page 137.

PII: S0033-0620(10)00121-0

doi: 10.1016/j.pcad.2010.07.001

Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 130-139 , September 2010

Article Tools